Jaeseung Kim

USPTO Granted Patents = 12 (Patent Applications = 12)

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 20)

Average Co-Inventor Count = 8.3

ph-index = 2

Forward Citations = 41(Granted Patents)

Location History:

Gangnam-gu, KR (2022)
Seoul, KR (2014 - 2024)

Company Filing History:

Institut Pasteur Korea

patents

3 out of 14

Lead Discovery Center Gmbh

patents

4. 2 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410165 - Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide (2025-09-09),

2. 12227524 - Anti-infective compounds (2025-02-18),

3. 12162858 - Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R (2024-12-10),

4. 11945822 - Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase (2024-04-02),

5. 11858937 - Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2024-01-02),

6. 11447486 - 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors (2022-09-20),

7. 11279714 - Anti-infective compounds (2022-03-22),

8. 10934274 - Quinoline derivatives as TAM RTK inhibitors (2021-03-02),

9. 9855243 - Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation (2018-01-02),

10. 9029389 - Anti-inflammation compounds (2015-05-12),

11. 8865734 - Anti-infective compounds (2014-10-21),

12. 8785452 - Anti-infective compounds (2014-07-22),

Title: Jaeseung Kim: Innovator in Anti-Infective and Oncological Compounds

Introduction: Jaeseung Kim is a prominent inventor based in Seoul, South Korea. With a remarkable portfolio of 11 patents, he has made significant contributions to the fields of medicine, particularly in developing treatments for bacterial infections and cancer-related disorders. His innovative work demonstrates a commitment to improving health outcomes through the discovery of novel compounds.

Latest Patents: Among his latest patents, Kim has developed anti-infective compounds that target bacterial infections, specifically tuberculosis. This invention involves small molecule compounds designed to effectively combat this serious health issue. Additionally, Kim's work on quinoline derivatives has resulted in inhibitors for AXL/MER RTK and CSF1R, which are crucial in addressing hyperproliferative disorders such as cancer. These compounds hold potential for treating various conditions, including cancer metastases, inflammatory diseases, and neurodegenerative diseases.

Career Highlights: Jaeseung Kim has built a distinguished career, working with esteemed organizations such as Qurient Co., Ltd. and Institut Pasteur Korea. His contributions in these institutions reflect his dedication to research and development in the pharmaceutical field. His extensive experience has positioned him as a leader in the innovation of therapeutic agents.

Collaborations: Throughout his career, Kim has collaborated with talented colleagues, including Kiyean Nam and Sunhee Kang. These collaborations have fostered an environment of innovation and have played a critical role in the advancement of his research efforts.

Conclusion: Jaeseung Kim represents the spirit of innovation in the fight against infectious diseases and cancer. His 11 patents and ongoing research exemplify the important role of inventors in addressing global health challenges. As he continues to push the boundaries of scientific discovery, his contributions are sure to have a lasting impact on the medical field.

This text is generated by artificial intelligence and may not be accurate.